

## Healthcare Specialist

14 June 2007 | News

image not found or type unknown



### Healthcare Specialist

*Bharat Biotech was established in 1996 with the objective of manufacturing unique vaccines and biotherapeutics.*

Bharat Biotech International

Business: Manufacturer of human vaccines and biopharmaceuticals

CEO: Dr Krishna M Ella

Biotech Revenue: Rs 70.27 crore

Start-up Year: 1996

New initiatives: Manufacture of human rabies vaccines, formulation of various vaccines and biopharmaceuticals. Address: Road No. 65 Jubilee Hills, Hyderabad

Tel.: 91-40-23480567/55510150

Fax: 91-40-23480560

Website: [www.bharatbiotech.com](http://www.bharatbiotech.com)

Hyderabad-based Bharat Biotech International Ltd (BBIL) is a multidimensional biotechnology company specializing in product-oriented research, development and manufacturing of vaccines and biotherapeutics through innovative and collaborative research.

Bharat Biotech has set a precedent in this emerging area with the manufacture of HibTITER (Haemophilus Influenzae b Conjugate Vaccine) for Wyeth Lederle Ltd. This was the first time that a vaccine was moved out of the US for manufacturing in India. BBIL is also manufacturing a cancer therapeutic for US-based Agennix.

Bharat Biotech International has a strategic alliance with Novavax to pursue the rapid development of pandemic influenza vaccine for India and other ASEAN markets. Under the terms of the agreement, Bharat Biotech will fund all pre-clinical and clinical development, work with Novavax on optimal manufacturing processes, and be responsible for the commercialization of the vaccine. In return Novavax will receive unrestricted access to all pre-clinical and clinical data, and a royalty on all sales.

BBIL has also signed a license agreement with ThromboGenics NV for manufacturing, clinical development and commercialization of THR-100, a novel variant of recombinant staphylokinase, in developing countries and certain industrialized countries. THR-100 is a thrombolytic agent developed for treatment of acute myocardial infarction (AMI or heart attack) and other vascular diseases based on its ability to dissolve blood clots. In return for granting this license, ThromboGenics will earn double digit royalties on net sales. Bharat Biotech will assume responsibility for all future costs. THR-100 has completed Phase II clinical trials in Europe for treatment of AMI in over 140 patients.

Bharat Biotech, with its core vaccine competence, has indigenously developed and introduced for the first time as one of its kind, chromatographically purified vero cell vaccine, INDIRAB in December 2006. INDIRAB can be used for both prophylactic vaccine (pre-bite) and therapeutic (post-bite) treatments.

Recently, UK-based Acambis announced the launch of clinical trials of its new, single-dose Japanese Encephalitis (JE) vaccine in children in India in collaboration with Bharat Biotech. Once approved, the vaccine will be marketed and distributed in India and neighboring countries by Bharat Biotech.